Elanco Animal Health Inc (ELAN) stock
ELANNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30146% above fair value
$25.74−0.55 (-2.09%)
Close on Nov 20, 2026Market cap $12.86BP/E –Yield –
Elanco Animal Health shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Elanco Animal Health's shares outstanding was 506M at Jun 30, 2026. For fiscal 2025 it was 496M, down 0.2% from the year before. The highest annual figure on record is 497M in fiscal 2024.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 496M | -0.2% |
| FY2024 | Dec 31, 2024 | 497M | +1.0% |
| FY2023 | Dec 31, 2023 | 492M | +0.8% |
| FY2022 | Dec 31, 2022 | 488M | +0.2% |
| FY2021 | Dec 31, 2021 | 487M | +10.4% |
| FY2020 | Dec 31, 2020 | 441M | +19.2% |
| FY2019 | Dec 31, 2019 | 370M | +18.0% |
| FY2018 | Dec 31, 2018 | 314M | +7.0% |
| FY2017 | Dec 31, 2017 | 293M | 0.0% |
| FY2016 | Dec 31, 2016 | 293M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 506M | +1.2% |
| Q1 FY2026 | Mar 31, 2026 | 506M | +1.4% |
| Q4 FY2025 | Dec 31, 2025 | 482M | -3.3% |
| Q3 FY2025 | Sep 30, 2025 | 497M | -0.2% |
| Q2 FY2025 | Jun 30, 2025 | 500M | +1.2% |
| Q1 FY2025 | Mar 31, 2025 | 499M | +0.6% |
| Q4 FY2024 | Dec 31, 2024 | 499M | +1.1% |
| Q3 FY2024 | Sep 30, 2024 | 498M | +1.0% |
| Q2 FY2024 | Jun 30, 2024 | 494M | +0.3% |
| Q1 FY2024 | Mar 31, 2024 | 496M | +0.6% |
| Q4 FY2023 | Dec 31, 2023 | 493M | +0.9% |
| Q3 FY2023 | Sep 30, 2023 | 493M | +0.9% |
| Q2 FY2023 | Jun 30, 2023 | 493M | +0.9% |
| Q1 FY2023 | Mar 31, 2023 | 493M | +0.1% |
| Q4 FY2022 | Dec 31, 2022 | 488M | +0.2% |
| Q3 FY2022 | Sep 30, 2022 | 488M | +0.2% |
| Q2 FY2022 | Jun 30, 2022 | 488M | +0.2% |
| Q1 FY2022 | Mar 31, 2022 | 492M | +1.1% |
| Q4 FY2021 | Dec 31, 2021 | 487M | +0.3% |
| Q3 FY2021 | Sep 30, 2021 | 487M | +5.4% |
| Q2 FY2021 | Jun 30, 2021 | 487M | +17.9% |
| Q1 FY2021 | Mar 31, 2021 | 487M | +20.5% |
| Q4 FY2020 | Dec 31, 2020 | 486M | +29.6% |
| Q3 FY2020 | Sep 30, 2020 | 462M | +23.9% |
| Q2 FY2020 | Jun 30, 2020 | 413M | +12.6% |
| Q1 FY2020 | Mar 31, 2020 | 404M | +10.4% |
| Q4 FY2019 | Dec 31, 2019 | 375M | +2.3% |
| Q3 FY2019 | Sep 30, 2019 | 373M | +23.9% |
| Q2 FY2019 | Jun 30, 2019 | 367M | +25.1% |
| Q1 FY2019 | Mar 31, 2019 | 366M | +24.8% |
| Q4 FY2018 | Dec 31, 2018 | 367M | +0.3% |
| Q3 FY2018 | Sep 30, 2018 | 301M | – |
| Q2 FY2018 | Jun 30, 2018 | 293M | – |
| Q1 FY2018 | Mar 31, 2018 | 293M | – |
| Q3 FY2017 | Sep 30, 2017 | 366M | – |
See a number that looks wrong?